450 Day Assessment Results for the First 13 Phase 2 PatientsThese are available from the
MD&A from November 29, 2021 on sedar:
"As of November 29, 2021, Study II has enrolled and provided the primary study treatment for 30 patients (including three patients from the Study treated at the Therapeutic Dose) for a total of 33 patients, providing the following interim results, with significant clinical data still pending:" Here is the portion of the chart dedicated to the 450 day assessment.
| Assessment Day | 450 Days |
| # | % |
| Complete Response ("CR") | 4 | 12.10% |
| Partial Response ("PR") | 2 | 6.10% |
| Pending | 17 | 51.50% |
| No Response ("NR") | 10 | 30.30% |
| Total Treated | 33 | 100% |
If we remove the 3 phase 1 patients (
2 CRs and 1 NR) and the
17 pending patients who have not yet been assessed at 450 days we are left with a total of
13 patients. These
13 patients are comprised of the
first 12 undertreated patients plus
the first patient to receive only optimized treatments. A revised chart of just these 13 patients at 450 days looks like this:
| Assessment Day | 450 Days |
| # | % |
| Complete Response ("CR") | 2 | 15% |
| Partial Response ("PR") | 2 | 15% |
| No Response ("NR") | 9 | 69% |
| Total Treated | 13 | 13 |
Assuming patient 13 was either a CR or a PR, 3 of the first 12 patients responded to the treatment - either 2 were CR and 1 was PR, or 1 was CR and 2 were PR at 450 days. 9 of the first 12 patient were NR (assuming patient 13 was not NR)